Novel uses of 2-phenyl-substituted imidazotriazinone...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/53 (2006.01) A61P 9/00 (2006.01) A61P 15/00 (2006.01) A61P 25/00 (2006.01) A61P 43/00 (2006.01)

Patent

CA 2575907

The invention relates to the use of PDE 5 inhibitors, and especially of known 2-phenyl-substituted imidazotriazinone derivatives for producing medicaments for the treatment of symptoms that can be treated by increasing cGMP levels in certain tissues, such as acute myocardial infarction and damage caused by reperfusion, various symptoms in the female and male reproductive system and urogenital tract, gastrointestinal diseases, damage caused by diabetes, and liver failure.

L'invention concerne l'utilisation en général d'inhibiteurs de la PDE 5 et en particulier de dérivés connus d'imidazotriazinones substituées par 2-phényle pour produire des médicaments servant à traiter des syndromes qui peuvent être soignés par élévation des taux de cGMP dans certains tissus, par exemple l'infarctus aigu du myocarde et les lésions de reperfusion, différents syndromes de l'appareil reproducteur et de l'appareil génito-urinaire chez la femme et chez l'homme, les infections gastro-intestinales, les lésions diabétiques et les défaillances rénales.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Novel uses of 2-phenyl-substituted imidazotriazinone... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel uses of 2-phenyl-substituted imidazotriazinone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel uses of 2-phenyl-substituted imidazotriazinone... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1466668

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.